Based on our previous study identifying neuroinflammation as robust amplifier of two disease-related PLP1 mutations leading to PLP loss-of-function [8], we aimed to investigate whether the respective inflammatory reactions are treatable with an established immune modulator initially designed for relapsing-remitting multiple sclerosis [23]. This evidence concerns the gene PLP1 and relapsing-remitting multiple sclerosis.